Concepts (190)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Opioid-Related Disorders | 12 | 2025 | 456 | 4.120 |
Why?
|
Buprenorphine | 9 | 2025 | 181 | 4.070 |
Why?
|
Opiate Substitution Treatment | 9 | 2025 | 187 | 2.330 |
Why?
|
Eczema | 6 | 2023 | 9 | 1.270 |
Why?
|
Dermatitis, Atopic | 6 | 2023 | 27 | 1.250 |
Why?
|
Hypertension | 3 | 2023 | 568 | 1.240 |
Why?
|
Telemedicine | 2 | 2024 | 307 | 1.210 |
Why?
|
Narcotic Antagonists | 4 | 2025 | 121 | 1.140 |
Why?
|
Substance Withdrawal Syndrome | 2 | 2024 | 119 | 0.970 |
Why?
|
Antihypertensive Agents | 2 | 2015 | 162 | 0.860 |
Why?
|
Asthma | 5 | 2023 | 453 | 0.780 |
Why?
|
Smoking Cessation | 7 | 2022 | 541 | 0.730 |
Why?
|
Drug Overdose | 1 | 2023 | 126 | 0.730 |
Why?
|
Mobile Applications | 1 | 2022 | 129 | 0.700 |
Why?
|
Health Promotion | 2 | 2015 | 471 | 0.650 |
Why?
|
Quality Indicators, Health Care | 2 | 2019 | 332 | 0.620 |
Why?
|
Prisons | 6 | 2022 | 105 | 0.600 |
Why?
|
Substance Abuse, Intravenous | 1 | 2018 | 74 | 0.560 |
Why?
|
Substance Abuse Treatment Centers | 1 | 2018 | 103 | 0.560 |
Why?
|
Dental Care | 1 | 2017 | 9 | 0.560 |
Why?
|
Hepatitis C, Chronic | 1 | 2018 | 88 | 0.550 |
Why?
|
Humans | 37 | 2025 | 59360 | 0.530 |
Why?
|
Evidence-Based Medicine | 1 | 2018 | 442 | 0.520 |
Why?
|
Smoking Prevention | 4 | 2013 | 158 | 0.520 |
Why?
|
Oral Health | 1 | 2017 | 61 | 0.520 |
Why?
|
Fentanyl | 4 | 2025 | 72 | 0.500 |
Why?
|
Medical Records | 1 | 2016 | 133 | 0.500 |
Why?
|
Prisoners | 5 | 2015 | 151 | 0.480 |
Why?
|
Antiviral Agents | 1 | 2018 | 313 | 0.480 |
Why?
|
Documentation | 1 | 2016 | 127 | 0.480 |
Why?
|
Healthcare Disparities | 2 | 2017 | 326 | 0.470 |
Why?
|
Delivery of Health Care | 1 | 2017 | 408 | 0.420 |
Why?
|
Hypersensitivity | 2 | 2023 | 63 | 0.410 |
Why?
|
Lung Diseases | 1 | 2012 | 170 | 0.360 |
Why?
|
Smoking | 6 | 2022 | 826 | 0.360 |
Why?
|
Adult | 14 | 2025 | 15669 | 0.320 |
Why?
|
Male | 15 | 2025 | 27739 | 0.300 |
Why?
|
Cardiovascular Diseases | 1 | 2015 | 788 | 0.290 |
Why?
|
Tobacco Products | 2 | 2022 | 71 | 0.280 |
Why?
|
Patient Preference | 3 | 2025 | 78 | 0.280 |
Why?
|
Longitudinal Studies | 3 | 2024 | 1189 | 0.270 |
Why?
|
Patient-Centered Care | 3 | 2018 | 246 | 0.270 |
Why?
|
Stroke | 1 | 2015 | 1127 | 0.260 |
Why?
|
Quality Assurance, Health Care | 2 | 2019 | 251 | 0.250 |
Why?
|
Primary Health Care | 3 | 2021 | 643 | 0.240 |
Why?
|
Washington | 1 | 2024 | 23 | 0.230 |
Why?
|
Oregon | 1 | 2024 | 19 | 0.230 |
Why?
|
Anesthetics, Dissociative | 1 | 2024 | 7 | 0.230 |
Why?
|
Smoke-Free Policy | 2 | 2015 | 9 | 0.230 |
Why?
|
Ketamine | 1 | 2024 | 32 | 0.230 |
Why?
|
Janus Kinase Inhibitors | 1 | 2023 | 17 | 0.220 |
Why?
|
Dermatologic Agents | 1 | 2023 | 20 | 0.220 |
Why?
|
Sublingual Immunotherapy | 1 | 2022 | 1 | 0.210 |
Why?
|
Female | 13 | 2025 | 30705 | 0.210 |
Why?
|
Patient Participation | 1 | 2025 | 216 | 0.200 |
Why?
|
Buprenorphine, Naloxone Drug Combination | 1 | 2022 | 25 | 0.200 |
Why?
|
Practice Guidelines as Topic | 2 | 2018 | 705 | 0.200 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2022 | 39 | 0.200 |
Why?
|
Naloxone | 1 | 2022 | 57 | 0.190 |
Why?
|
Social Stigma | 1 | 2022 | 64 | 0.190 |
Why?
|
Middle Aged | 7 | 2025 | 16317 | 0.190 |
Why?
|
Analgesics, Opioid | 2 | 2025 | 483 | 0.190 |
Why?
|
Smartphone | 1 | 2022 | 64 | 0.190 |
Why?
|
United States | 7 | 2023 | 7390 | 0.180 |
Why?
|
Young Adult | 3 | 2022 | 4267 | 0.170 |
Why?
|
Central Nervous System Agents | 1 | 2018 | 6 | 0.160 |
Why?
|
Diagnostic Techniques and Procedures | 1 | 2018 | 8 | 0.150 |
Why?
|
Induction Chemotherapy | 1 | 2018 | 31 | 0.150 |
Why?
|
Cohort Studies | 1 | 2024 | 2374 | 0.150 |
Why?
|
Substance Abuse Detection | 1 | 2018 | 44 | 0.150 |
Why?
|
Systems Integration | 1 | 2018 | 26 | 0.150 |
Why?
|
Benzodiazepines | 1 | 2018 | 94 | 0.150 |
Why?
|
Drug Therapy, Combination | 1 | 2018 | 452 | 0.140 |
Why?
|
Epidemics | 1 | 2017 | 22 | 0.140 |
Why?
|
Survival Rate | 1 | 2019 | 802 | 0.140 |
Why?
|
Patient Compliance | 1 | 2019 | 349 | 0.140 |
Why?
|
Recurrence | 1 | 2018 | 603 | 0.130 |
Why?
|
Motivation | 2 | 2022 | 273 | 0.130 |
Why?
|
Cotinine | 2 | 2013 | 19 | 0.130 |
Why?
|
Physician-Patient Relations | 2 | 2018 | 396 | 0.130 |
Why?
|
Counseling | 1 | 2018 | 349 | 0.130 |
Why?
|
Medical History Taking | 1 | 2016 | 65 | 0.130 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2017 | 112 | 0.120 |
Why?
|
Workload | 1 | 2016 | 118 | 0.120 |
Why?
|
Efficiency, Organizational | 1 | 2016 | 94 | 0.120 |
Why?
|
Homicide | 1 | 2015 | 27 | 0.120 |
Why?
|
Poverty | 1 | 2017 | 281 | 0.120 |
Why?
|
Blood Pressure Determination | 1 | 2014 | 37 | 0.120 |
Why?
|
Physicians, Primary Care | 1 | 2015 | 72 | 0.110 |
Why?
|
Reference Values | 1 | 2014 | 326 | 0.110 |
Why?
|
Burnout, Professional | 1 | 2016 | 125 | 0.110 |
Why?
|
Network Meta-Analysis | 2 | 2023 | 12 | 0.110 |
Why?
|
Family Health | 1 | 2014 | 67 | 0.110 |
Why?
|
Violence | 1 | 2015 | 146 | 0.110 |
Why?
|
Personal Autonomy | 1 | 2013 | 68 | 0.100 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2023 | 677 | 0.100 |
Why?
|
Motivational Interviewing | 1 | 2013 | 42 | 0.100 |
Why?
|
Mass Screening | 1 | 2018 | 645 | 0.100 |
Why?
|
Pruritus | 2 | 2023 | 29 | 0.100 |
Why?
|
Health Services Accessibility | 1 | 2017 | 521 | 0.100 |
Why?
|
Blood Pressure | 1 | 2014 | 495 | 0.100 |
Why?
|
Quality of Life | 3 | 2023 | 1137 | 0.100 |
Why?
|
Emergencies | 1 | 2012 | 111 | 0.090 |
Why?
|
Health Status | 1 | 2014 | 424 | 0.090 |
Why?
|
Surveys and Questionnaires | 3 | 2014 | 2513 | 0.090 |
Why?
|
Skin Diseases | 1 | 2012 | 76 | 0.090 |
Why?
|
Family Practice | 1 | 2012 | 207 | 0.080 |
Why?
|
Aged | 3 | 2022 | 13416 | 0.080 |
Why?
|
Adolescent | 2 | 2023 | 5824 | 0.080 |
Why?
|
Severity of Illness Index | 1 | 2014 | 1479 | 0.080 |
Why?
|
Hospitals, Urban | 1 | 2009 | 43 | 0.080 |
Why?
|
Hospitals, University | 1 | 2009 | 52 | 0.080 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2013 | 724 | 0.080 |
Why?
|
Risk Assessment | 1 | 2014 | 1921 | 0.070 |
Why?
|
Emergency Service, Hospital | 2 | 2018 | 1021 | 0.070 |
Why?
|
Algorithms | 1 | 2012 | 976 | 0.070 |
Why?
|
Prospective Studies | 1 | 2012 | 3067 | 0.060 |
Why?
|
Communication | 2 | 2018 | 545 | 0.060 |
Why?
|
Patient Discharge | 1 | 2009 | 489 | 0.060 |
Why?
|
Administration, Sublingual | 1 | 2024 | 3 | 0.060 |
Why?
|
Child | 2 | 2023 | 4174 | 0.050 |
Why?
|
Patient Care Team | 2 | 2009 | 326 | 0.050 |
Why?
|
Tacrolimus | 1 | 2023 | 62 | 0.050 |
Why?
|
Methadone | 1 | 2024 | 127 | 0.050 |
Why?
|
Dermatophagoides pteronyssinus | 1 | 2022 | 2 | 0.050 |
Why?
|
Pyroglyphidae | 1 | 2022 | 3 | 0.050 |
Why?
|
Desensitization, Immunologic | 1 | 2022 | 9 | 0.050 |
Why?
|
Allergens | 1 | 2022 | 49 | 0.050 |
Why?
|
Bayes Theorem | 1 | 2022 | 109 | 0.050 |
Why?
|
Adrenal Cortex Hormones | 1 | 2023 | 169 | 0.050 |
Why?
|
Immunoglobulin E | 1 | 2022 | 86 | 0.050 |
Why?
|
Immunosuppressive Agents | 1 | 2023 | 365 | 0.050 |
Why?
|
Odds Ratio | 2 | 2014 | 745 | 0.050 |
Why?
|
Nephrology | 1 | 2001 | 15 | 0.050 |
Why?
|
Endocrinology | 1 | 2001 | 21 | 0.050 |
Why?
|
Pilot Projects | 1 | 2024 | 914 | 0.050 |
Why?
|
Group Processes | 1 | 2001 | 41 | 0.050 |
Why?
|
Qualitative Research | 1 | 2025 | 618 | 0.040 |
Why?
|
Caregivers | 1 | 2023 | 231 | 0.040 |
Why?
|
Interprofessional Relations | 1 | 2001 | 129 | 0.040 |
Why?
|
Education, Medical, Undergraduate | 1 | 2001 | 151 | 0.040 |
Why?
|
Rural Population | 1 | 2021 | 185 | 0.040 |
Why?
|
Program Evaluation | 2 | 2017 | 470 | 0.040 |
Why?
|
Diet | 1 | 2022 | 497 | 0.040 |
Why?
|
Students, Medical | 1 | 2001 | 245 | 0.040 |
Why?
|
Infant | 1 | 2022 | 1486 | 0.040 |
Why?
|
Diagnostic Errors | 1 | 2018 | 95 | 0.040 |
Why?
|
Anti-Bacterial Agents | 1 | 2023 | 735 | 0.040 |
Why?
|
Missouri | 1 | 2017 | 9 | 0.040 |
Why?
|
Continuity of Patient Care | 1 | 2018 | 170 | 0.030 |
Why?
|
Health Policy | 1 | 2018 | 176 | 0.030 |
Why?
|
Cooperative Behavior | 1 | 2017 | 210 | 0.030 |
Why?
|
Self Care | 1 | 2017 | 207 | 0.030 |
Why?
|
Referral and Consultation | 1 | 2018 | 398 | 0.030 |
Why?
|
Evidence-Based Practice | 1 | 2015 | 79 | 0.030 |
Why?
|
Respiratory Sounds | 1 | 2015 | 22 | 0.030 |
Why?
|
Rhode Island | 1 | 2015 | 97 | 0.030 |
Why?
|
Fatigue | 1 | 2015 | 103 | 0.030 |
Why?
|
Chest Pain | 1 | 2015 | 81 | 0.030 |
Why?
|
Dyspnea | 1 | 2015 | 116 | 0.030 |
Why?
|
New England | 1 | 2013 | 267 | 0.030 |
Why?
|
Treatment Outcome | 1 | 2023 | 5284 | 0.030 |
Why?
|
Cough | 1 | 2015 | 183 | 0.030 |
Why?
|
Intention | 1 | 2013 | 64 | 0.030 |
Why?
|
Secondary Prevention | 1 | 2013 | 151 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 2015 | 412 | 0.020 |
Why?
|
Dermatitis, Exfoliative | 1 | 2012 | 3 | 0.020 |
Why?
|
Purpura | 1 | 2012 | 3 | 0.020 |
Why?
|
Fasciitis, Necrotizing | 1 | 2012 | 4 | 0.020 |
Why?
|
Mucocutaneous Lymph Node Syndrome | 1 | 2012 | 12 | 0.020 |
Why?
|
Blister | 1 | 2012 | 17 | 0.020 |
Why?
|
Physical Examination | 1 | 2012 | 104 | 0.020 |
Why?
|
Psoriasis | 1 | 2012 | 50 | 0.020 |
Why?
|
Soft Tissue Infections | 1 | 2012 | 45 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2013 | 902 | 0.020 |
Why?
|
Chronic Disease | 1 | 2014 | 716 | 0.020 |
Why?
|
Social Support | 1 | 2013 | 355 | 0.020 |
Why?
|
Logistic Models | 1 | 2013 | 1232 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2012 | 937 | 0.020 |
Why?
|
Cost Savings | 1 | 2009 | 52 | 0.020 |
Why?
|
Follow-Up Studies | 1 | 2014 | 2337 | 0.020 |
Why?
|
Neoplasms | 1 | 2018 | 1240 | 0.020 |
Why?
|
Emergency Medical Services | 1 | 2012 | 255 | 0.020 |
Why?
|
Boston | 1 | 2009 | 246 | 0.020 |
Why?
|
Biomarkers | 1 | 2013 | 1306 | 0.020 |
Why?
|
Time Factors | 1 | 2013 | 3617 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2009 | 453 | 0.020 |
Why?
|
Animals | 1 | 2022 | 19651 | 0.010 |
Why?
|
Hospitalization | 1 | 2009 | 1290 | 0.010 |
Why?
|
Attitude of Health Personnel | 1 | 2001 | 550 | 0.010 |
Why?
|